DERMATOLOGICAL COMPOSITION AUGMENTING PARACRINE SIGNALLING
A composition facilitating healthy skin by augmenting natural paracrine to improve and/or maintain replenishment by utilizing a therapeutic effective amount of at a least one an angio-modifying formulation, a morphogenesis formulation, an extracellular matrix formulation, an extracellular matrix modification formulation, an immune promoting formulation and a cytoskeleton formulation.
1 . A dermatological composition, comprising:
a therapeutic effective amount of an angio-modifying formulation comprising agrin isoform 6 and calpastatin isoform 6.
2 . The composition of claim 1 , wherein the angio-modifying formulation further comprises jagged-1
3 . The composition of claim 1 , wherein the angio-modifying formulation further comprises isoform 2 of growth arrest-specific protein 6.
4 . The composition of claim 1 , wherein the angio-modifying formulation further comprises vascular endothelial growth factor C.
5 . The composition of claim 1 , further comprising a therapeutic effective amount of a morphogenesis formulation comprising tenascin isoform 4 and fibronectin isoform 3.
6 . The composition of claim 5 , wherein the morphogenesis formulation further comprises transforming growth factor beta induced protein ig-h3.
7 . The composition of claim 5 , wherein the morphogenesis formulation further comprises a long isoform Kazal-type 5 serine protease inhibitor.
8 . The composition of claim 5 , wherein the morphogenesis formulation further comprises a plasminogen activator inhibitor 1 serein protease inhibitor.
9 . The composition of claim 5 , wherein the morphogenesis formulation further comprises receptor type tyrosine-protein phosphatase kappa.
10 . The composition of claim 5 , wherein the morphogenesis formulation further comprises keratinocyte proline-rich protein.
11 . The composition of claim 5 , wherein the morphogenesis formulation further comprises pappalysin-1.
12 . The composition of claim 1 , further a therapeutic effective amount of an extracellular matrix formulation comprising laminin subunit alpha 3.
13 . The composition of claim 12 , wherein the extracellular matrix formulation further comprises laminin subunit beta-3.
14 . The composition of claim 12 , wherein the extracellular matrix formulation further comprises laminin subunit gamma-2.
15 . The composition of claim 12 , wherein the extracellular matrix formulation further comprises laminin-332.
16 . The composition of claim 1 , further comprising a therapeutic effective amount of an immune promoting formulation comprising serapin B7, complement component C1s and complement component C3.
17 . The composition of claim 16 , wherein the immune promoting formulation further comprises a neutrophil chemotactic agent.
18 . The composition of claim 1 , further comprising a therapeutic effective amount of an extracellular matrix modification formulation comprising interstitial collagenase and stomelysin-1.
19 . The composition of claim 18 , wherein the extracellular matrix modification formulation further comprises latent-transforming growth factor beta-binding protein 2
20 . The composition of claim 18 , wherein the extracellular matrix modification formulation further comprises tissue factor pathway inhibitor 2.
21 . A method of treating a skin condition comprising:
applying to the skin a dermatological composition comprising a therapeutic effective amount of at a least one an angio-modifying formulation, a morphogenesis formulation, an extracellular matrix formulation, an extracellular matrix modification formulation, an immune promoting formulation and a cytoskeleton formulation,
wherein the skin condition comprises at least one of wrinkles, eczema, acne, impetigo, psoriasis, rashes, rosacea and hives.
22 . The method of claim 21 , wherein the dermatological composition comprises a therapeutic effective amount of an angio-modifying formulation comprising agrin isoform 6 and calpastatin isoform 6.
23 . The method of claim 21 , wherein the dermatological composition comprises a therapeutic effective amount of a morphogenesis formulation comprising tenascin isoform 4 and fibronectin isoform 3.
24 . The method of claim 21 , wherein the dermatological composition comprises a therapeutic effective amount of an extracellular matrix formulation comprising laminin subunit alpha 3.
25 . The method of claim 21 , wherein the dermatological composition comprises a therapeutic effective amount of an immune promoting formulation comprising serapin B7, complement component C1s and complement component C3.
26 . The method of claim 21 , wherein the dermatological composition comprises a therapeutic effective amount of an extracellular matrix modification formulation comprising interstitial collagenase and stomelysin-1.